NEW YORK and HERTFORDSHIRE, England and PITTSBURGH, April 18, 2019 /PRNewswire/ — Non-profit drug developer, TB Alliance, and pharmaceutical company
Source: www.prnewswire.com
Mylan N.V. (NASDAQ: MYL), a pharmaceutical company and TB Alliance, a non-profit drug developer have announced a global collaboration to make the experimental drug pretomanid. This drug is available for use in two investigational drug regimens to treat tuberculosis (TB). TB Alliance is currently developing pretomanid in three late-stage clinical trials. Nix-TB and ZeNix trials are evaluating the BPaL regimen to treat XDR-TB and the related highly resistant forms of TB, and SimpliciTB trial is evaluating the BPaMZ regimen for treating DS-TB in four months, and MDR-TB in six months.
